# The Role of Exogenous Type VII Collagen on the Healing of Skin Wounds

> **NIH VA I01** · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · 2021 · —

## Abstract

We have made the surprising finding that type VII (anchoring fibril) collagen (C7) exogenously administered
to murine skin wounds, both topically and intravenously, induces dramatic acceleration of wound closure and
the wounds heal with less scarring. This was an unexpected finding because, under normal conditions in
unwounded skin, C7 is configured into large structures called anchoring fibrils which are confined to the
junction between the dermis and epidermis, the dermal-epidermal junction (DEJ). For many years, we have
studied the structure and function of C7 and were surprised to find that in the wound bed of healing skin
wounds, C7 is not confined to the DEJ, but, rather, is widely distributed throughout the wound bed. We also
developed procedures for making milligram quantities of recombinant human type VII collagen (rhC7). We
added rhC7 to 1 x 1 cm standard full-thickness wounds on the backs of hairless mice and evaluated wound
closure. We found that compared with vehicle control or no treatment, rhC7-treated wounds exhibited
dramatic acceleration of wound closure. The same results also occurred when we treated skin wounds made
in diabetic mice who exhibit delayed skin wound healing. We also transplanted human skin onto the backs of
athymic mice, wounded the transplanted human skin and applied either vehicle or rhC7. Again, rhC7 induced
accelerated wound closure in the human skin compared with the vehicle. rhC7 had specific activity since
other large macromolecules (type I collagen, type IV collagen, fibronectin, and laminin 332) did not accelerate
wound closure in these animals. It was also noted that the murine skin wounds treated with rhC7 healed with
less clinical scarring. We then evaluated vehicle- and rhC7-treated murine wounds by histology and by
immunohistochemistry for markers of scarring. Compared with vehicle-treated wounds, murine skin wounds
treated with rhC7 exhibited a dramatic down-regulation of markers of scarring including collagen deposition,
smooth muscle actin positive fibroblasts (myofibroblasts), connective tissue growth factor, periostin and pro-
fibrotic isoforms of transforming growth factor beta (TGFb). Given these unexpected dramatic results, the
subject of this grant is the role of C7 in the healing of skin wounds. Recently, we have also established
the first and only diabetic pig with delayed healing of skin wounds. In this proposal, we wish to determine the
influence of topically administered rhC7 on skin wounds made in domestic pigs, both normal and diabetic.
Performing experiments with pigs is critical because pigskin is much more relevant to human skin. Pigs are
tight-skinned animals and have skin the most similar to human skin. Pigs are the species of choice for wound
healing studies. We will also determine if topical rhC7 inhibits scarring and generates elements of
“regenerative” healing rather than just “reparative” healing. We will also establish the stability of rhC7 in
pigskin wounds as a surrogate...

## Key facts

- **NIH application ID:** 10200645
- **Project number:** 5I01BX002028-07
- **Recipient organization:** VA GREATER LOS ANGELES HEALTHCARE SYSTEM
- **Principal Investigator:** DAVID T. WOODLEY
- **Activity code:** I01 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2021
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2014-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10200645

## Citation

> US National Institutes of Health, RePORTER application 10200645, The Role of Exogenous Type VII Collagen on the Healing of Skin Wounds (5I01BX002028-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10200645. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*